Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
08 août 2023 16h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1...
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
13 juil. 2023 23h15 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of...
Caribou Biosciences Announces Proposed Public Offering of Common Stock
13 juil. 2023 16h03 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has...
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
13 juil. 2023 16h01 HE
|
Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR)...
Caribou Biosciences to Participate in Upcoming Investor Conferences
31 mai 2023 16h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
09 mai 2023 16h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients...
Caribou Biosciences to Participate in Upcoming Investor Conferences
01 mai 2023 16h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting
17 avr. 2023 13h30 HE
|
Caribou Biosciences, Inc.
-- CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models -- -- CB-012 IND-enabling studies ongoing; IND submission in r/r AML...
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
20 mars 2023 01h45 HE
|
Bernstein Liebhard LLP
Did you lose money on investments in Caribou Biosciences? If so, please visit Caribou Biosciences, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212)...
CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)
13 mars 2023 01h45 HE
|
Bernstein Liebhard LLP
Did you lose money on investments in Caribou Biosciences? If so, please visit Caribou Biosciences, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212)...